Impact of Human Papillomavirus Vaccination in Reducing Cancer

Human papillomavirus (HPV) is a significant cause of global morbidity and mortality. A nonavalent HPV vaccine is widely available and recommended for routine use at 11 to 12  years old. Older teens and adults though age 45 years also could be offered vaccination. Widespread use of the HPV vaccine appears to impact the rate of infections and cancers. Some parents/teens may hesitate to be vaccinated. The strongest predictor to receiving the vaccine remains a trusted hea lth care professional making a strong recommendation to receive the vaccine. New HPV vaccines are in the pipeline, including therapeutic vaccines to treat HPV-related cancers.
Source: Primary Care: Clinics in Office Practice - Category: Primary Care Authors: Source Type: research